91493-56-0Relevant academic research and scientific papers
Identification and Optimization of the First Highly Selective GLUT1 Inhibitor BAY-876
Siebeneicher, Holger,Cleve, Arwed,Rehwinkel, Hartmut,Neuhaus, Roland,Heisler, Iring,Müller, Thomas,Bauser, Marcus,Buchmann, Bernd
supporting information, p. 2261 - 2271 (2016/10/24)
Despite the long-known fact that the facilitative glucose transporter GLUT1 is one of the key players safeguarding the increase in glucose consumption of many tumor entities even under conditions of normal oxygen supply (known as the Warburg effect), only
GLUCOSE TRANSPORT INHIBITORS
-
Page/Page column 129; 130; 162, (2015/07/07)
The present invention relates to chemical compounds that selectively inhibit glucose transporter 1 (GLUT1), to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds, to the use of said compounds for
NOVEL HIGH AFFINITY QUINOLINE-BASED KINASE LIGANDS
-
Paragraph 0279, (2014/01/09)
Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
Novel high affinity quinoline-based kinase ligands
-
Page/Page column 103, (2008/06/13)
Quinoline-based inhibitors of cyclin dependent kinase 2, compositions including the inhibitors, and methods of using the inhibitors and inhibitor compositions are described. The inhibitors and compositions including them are useful for treating disease or disease symptoms. The invention also provides for methods of making CDK-2 inhibitor compounds, methods of inhibiting CDK-2, and methods for treating disease or disease symptoms.
